You are here
P&T® Journal contents for November 2010
Health Care & Law
Makers of atypical antipsychotic medications are under scrutiny for promoting the off-label use of these agents, a practice that has led to serious adverse events and has cost the manufacturers billions of dollars in penalties.
Part 2: Ethical, Legal, and Regulatory Issues
The health care reform bill, privacy rules, health information technology, genetic testing, and a trend toward collaboration among federal agencies indicate that all stakeholders will have to change their business practices in the future.
With the passage of the Patient Protection and Affordable Care Act, five new categories of hospitals and clinics will be able to buy many drugs at reduced prices.
Sessions of the cardiovascular conference addressed the effect of statins on myocardial infarction, the safety of atopaxar (E5555) in acute coronary syndromes, and a comparison of clopidogrel (Plavix) and Prasugrel (Effient). The Parkinson meeting featured gastrointestinal absorption and the value of paroxetine (Paxil), venlafaxine (Effexor), and ritigotine (Neupro) in patients’ quality of life.
Topics include fingolimod capsules (Gilenya) for patients with relapsing multiple sclerosis; pegloticase (Krystexxa), an injectable product for gout; and Beyaz, a formulation of Yaz, an oral contraceptive that includes a folate vitamin to reduce the risk of neural tube defects.